Meeting Highlights
Perspectives for the Advanced Practitioner
Lindsey M. Lyle, MS, PA-C, on AML: Safety Analysis of Glasdegib
Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses the use of glasdegib in addition to intensive or nonintensive chemotherapy in patients with acute myeloid leukemia (Abstract 2732).
Sandra E. Kurtin, PhDc, ANP-C, AOCN, on Myeloid and Lymphoid Leukemias: A Dual Treatment Strategy
Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the dual inhibition of Bruton’s tyrosine kinase and BCL2; with the combination of venetoclax and ibrutinib, this drug combination may have broad therapeutic indications (Abstract 214).
Josh D. Epworth, MSN, ARNP, on Multiple Myeloma: Results From the Tourmaline-MM3 Trial
Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses study findings on maintenance therapy with the oral proteasome inhibitor ixazomib, which significantly prolonged progression-free survival following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma (Abstract 301).
Sandra E. Kurtin, PhDc, ANP-C, AOCN, on Treatment of CLL/SLL: 7-Year Follow-up Data
Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses phase Ib/II study findings on single-agent ibrutinib in the first-line and relapsed or refractory settings for chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 3133).
Lindsey M. Lyle, MS, PA-C, on AML: Early Findings on Quizartinib and Milademetan
Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses preclinical study findings on synergistic antileukemic activity with a combination of the FLT3 inhibitor quizartinib and the MDM2 inhibitor milademetan in FLT3-ITD–mutant/p53 wild-type acute myeloid leukemia models (Abstract 2720).
Josh D. Epworth, MSN, ARNP, on Multiple Myeloma: Results From the STORM Study
Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses study findings on pentarefractory multiple myeloma and the responses to oral selinexor plus low-dose dexamethasone (Abstract 598).
Sandra E. Kurtin, PhDc, ANP-C, AOCN, on CLL: Results From the MURANO Study
Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the first phase III prospective data on the impact of minimal residual disease on the long-term clinical outcomes with venetoclax plus rituximab vs bendamustine plus rituximab in chronic lymphocytic leukemia (Abstract 695).
Lindsey M. Lyle, MS, PA-C, on AML: Results From an Early Phase Dose-Escalation and Dose-Expansion Trial
Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses study findings on venetoclax in combination with hypomethylating agents, which induced rapid, deep, and durable responses in patients with acute myeloid leukemia who are ineligible for intensive therapy (Abstract 285).
Josh D. Epworth, MSN, ARNP, on Multiple Myeloma: Early Results From the PAVO Trial
Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses safety and efficacy data on subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma (Abstract 1995).